MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$490K
Net Income
-$123,797K
Net Profit Margin
-25264.69%
EPS
-$1.18
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
License and collaboration revenue
490
31,738
114,109
9,698
Research and development
95,096
104,524
99,275
109,769
General and administrative
31,947
34,429
32,279
26,740
Total operating expenses
127,043
138,953
131,554
136,509
Loss from operations
-126,553
-107,215
-17,445
-126,811
Change in fair value of derivative liabilities
-4,200
2,500
50
-2,757
Change in fair value of non-controlling equity investments
338
16
-3,329
4,937
Change in fair value of contingent consideration liabilities
205
-514
765
-1,000
Gain on sale of equity method investment
455
-
255,146
-
Interest and other income (expense), net
7,487
9,867
10,640
10,903
Total other income (expense)
3,875
12,897
261,742
14,083
Net gain before income taxes
-
-
244,297
-112,728
Net gain
-122,678
-94,318
244,297
-112,728
Unrealized gain (loss) on marketable securities
-1,119
-2,181
321
780
Comprehensive gain
-123,797
-96,499
244,618
-111,948
Basic EPS
-1.18
-0.91
2.373
-1.1
Diluted EPS
-1.18
-0.91
2.373
-1.1
Basic Average Shares
104,326,669
103,262,001
103,081,012
102,570,801
Diluted Average Shares
104,326,669
103,262,001
103,081,012
102,570,801
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive gain
-$123,797K
(-20.85%↓ Y/Y)
Interest and other income
(expense), net
$7,487K
(-39.26%↓ Y/Y)
Gain on sale of equity
method investment
$455K
Change in fair value of
non-controlling equity...
$338K
(-92.34%↓ Y/Y)
Net gain
-$122,678K
(-19.93%↓ Y/Y)
Unrealized gain (loss) on
marketable securities
-$1,119K
(-646.00%↓ Y/Y)
Total other income
(expense)
$3,875K
(-78.30%↓ Y/Y)
Change in fair value of
derivative liabilities
-$4,200K
(-466.17%↓ Y/Y)
Change in fair value of
contingent consideration...
$205K
(632.14%↑ Y/Y)
Loss from operations
-$126,553K
(-5.33%↓ Y/Y)
License and
collaboration revenue
$490K
(-94.21%↓ Y/Y)
Total operating
expenses
$127,043K
(-1.22%↓ Y/Y)
Research and development
$95,096K
(-6.55%↓ Y/Y)
General and
administrative
$31,947K
(18.94%↑ Y/Y)
Buy us a coffee
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)